Radiopharma player Pentixapharm absorbs Glycotope's discovery arm
2024-07-03
并购免疫疗法
Pentixapharm is bolstering its radiopharmaceutical pipeline through the acquisition of Glycotope's target discovery business for an undisclosed amount. The deal encompasses a portfolio of preclinical antibodies directed against several oncology markers that the company says could be the building blocks for a new generation of radiopharmaceuticals.
Beyond intellectual property, the acquisition includes Glycotope's laboratories, cell banks and tumour target database, along with patents, licenses, and other tangible assets. Pentixapharm will also integrate a team of 40 executives, R&D specialists, and administrators into its ranks.
According to CEO Hakim Bouterfa, the deal broadens Pentixapharm's intellectual property portfolio beyond its current focus on the CXCR4 receptor. The German company's existing pipeline features two key compounds. PentixaFor is a Gallium-68 PET imaging agent targeting the CXC receptor, which is overexpressed in various cancers. It's being developed for both oncology and cardiology applications. PentixaTher is a therapeutic counterpart to PentixaFor, equipped with the high energy beta emitter Yttrium-90 used for radioligand therapy of blood cancers.
More to follow.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。